Free Trial
NASDAQ:PLRX

Pliant Therapeutics (PLRX) Stock Price, News & Analysis

Pliant Therapeutics logo
$1.50 -0.05 (-2.92%)
As of 01:28 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Pliant Therapeutics Stock (NASDAQ:PLRX)

Advanced

Key Stats

Today's Range
$1.45
$1.51
50-Day Range
$1.43
$1.86
52-Week Range
$1.10
$16.10
Volume
610,339 shs
Average Volume
1.53 million shs
Market Capitalization
$91.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.19
Consensus Rating
Reduce

Company Overview

Pliant Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
83rd Percentile Overall Score

PLRX MarketRank™: 

Pliant Therapeutics scored higher than 83% of companies evaluated by MarketBeat, and ranked 211th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pliant Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.93, and is based on 1 buy rating, 11 hold ratings, and 2 sell ratings.

  • Upside Potential

    Pliant Therapeutics has a consensus price target of $8.19, representing about 447.7% upside from its current price of $1.50.

  • Amount of Analyst Coverage

    Pliant Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Pliant Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Pliant Therapeutics are expected to decrease in the coming year, from ($3.64) to ($3.72) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pliant Therapeutics is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pliant Therapeutics is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Pliant Therapeutics has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Pliant Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    6.09% of the outstanding shares of Pliant Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Pliant Therapeutics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pliant Therapeutics has recently increased by 11.31%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Pliant Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Pliant Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.09% of the outstanding shares of Pliant Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Pliant Therapeutics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pliant Therapeutics has recently increased by 11.31%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Pliant Therapeutics has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Pliant Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    13 people have searched for PLRX on MarketBeat in the last 30 days. This is an increase of 225% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Pliant Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pliant Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.00% of the stock of Pliant Therapeutics is held by insiders.

  • Percentage Held by Institutions

    97.30% of the stock of Pliant Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Pliant Therapeutics' insider trading history.
Receive PLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pliant Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PLRX Stock News Headlines

Shots officially fired…
Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the rights to deliver direct-to-cell service nationwide — a move tech analyst Jeff Brown says could shape the backbone of the coming space economy and create fortunes on a scale not seen since the rise of NVIDIA.tc pixel
Pliant Therapeutics Provides Update on BEACON-IPF
See More Headlines

PLRX Stock Analysis - Frequently Asked Questions

Pliant Therapeutics' stock was trading at $13.17 at the beginning of 2025. Since then, PLRX stock has decreased by 88.6% and is now trading at $1.4950.

Pliant Therapeutics, Inc. (NASDAQ:PLRX) posted its quarterly earnings results on Thursday, August, 7th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by $0.09.

Pliant Therapeutics (PLRX) raised $90 million in an IPO on Wednesday, June 3rd 2020. The company issued 6,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler served as the underwriters for the IPO and Needham & Company was co-manager.

Shares of PLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pliant Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
8/07/2025
Today
10/10/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PLRX
CIK
1746473
Fax
N/A
Employees
90
Year Founded
2016

Price Target and Rating

High Price Target
$38.00
Low Price Target
$1.50
Potential Upside/Downside
+454.7%
Consensus Rating
Reduce
Rating Score (0-4)
1.93
Research Coverage
14 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.40)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$210.30 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-73.45%
Return on Assets
-55.66%

Debt

Debt-to-Equity Ratio
0.14
Current Ratio
12.99
Quick Ratio
12.99

Sales & Book Value

Annual Sales
$1.58 million
Price / Sales
57.35
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.00 per share
Price / Book
0.30

Miscellaneous

Outstanding Shares
61,390,000
Free Float
56,477,000
Market Cap
$90.61 million
Optionable
Optionable
Beta
1.40

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:PLRX) was last updated on 10/10/2025 by MarketBeat.com Staff
From Our Partners